Evaluating Efficacy of a Unani Formulation in Hypertension

A Randomized, Parallel Group, Active Controlled Clinical Study to Evaluate Efficacy and Safety of a Unani Pharmacopoeial Formulation â?? Iksir-i Shifa in the Management of á¸?aght al- Dam QawÄ« LÄ?zimÄ« (Essential Hypertension)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036158

Enrollment

Registered

2021-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Iksir-i Shifa: Dosage form: Qurs (Tablet) Dose: One tablet (520 mg) twice daily with 250 ml of milk Route of administration: Oral Composition of Iksir-i Shifa 1. Asrol (Ra

Eligibility

Inclusion criteria

Inclusion criteria: i. Participants of any sex aged between 35-55 years ii. Stage-â? Hypertension according to JNC 7 (Systolic BP 140-159 and Diastolic BP 90-99 mmHg) iii. Participants willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: i. Participants with Secondary Hypertension (SBP >=160 mmHg and DBP >=100 mmHg) ii. Comorbidities condition iii. Pregnant and Lactating women iv. Drug Addicts, Alcoholics v. Participants not willing to give consent vi. Participants not willing to come for follow-up

Design outcomes

Primary

Measure	Time frame
Reduction in SBP â?¥15 mmHg and diastolic blood pressure â?¥ 10 mm Hg from base line. Timepoint: 45 DAYS	—

Secondary

Measure	Time frame
Systemic safety assessmentTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Qureshi Mohd Ansar Mohd Arshad

National Research Institute of Unani Medicine for Skin Disorders

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026